132,994 Shares in Enovis Corporation $ENOV Purchased by Legal & General Group Plc

Posted by on Sep 6th, 2026

Legal & General Group Plc bought a new position in Enovis Corporation (NYSE:ENOV – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 132,994 shares of the company’s stock, valued at approximately $2,753,000. Legal & General Group Plc owned about 0.23% of Enovis as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Arax Advisory Partners bought a new stake in shares of Enovis in the fourth quarter worth approximately $29,000. EverSource Wealth Advisors LLC boosted its holdings in Enovis by 125.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares during the last quarter. Allworth Financial LP purchased a new stake in Enovis in the second quarter worth approximately $36,000. Danske Bank A S bought a new stake in Enovis in the 3rd quarter worth approximately $64,000. Finally, iSAM Funds UK Ltd bought a new stake in Enovis in the 3rd quarter worth approximately $80,000. Institutional investors own 98.45% of the company’s stock.

Enovis Price Performance

NYSE ENOV opened at $18.58 on Friday. The company has a current ratio of 1.98, a quick ratio of 1.00 and a debt-to-equity ratio of 0.84. Enovis Corporation has a 12 month low of $18.52 and a 12 month high of $34.28. The stock has a market cap of $1.07 billion, a price-to-earnings ratio of -0.96 and a beta of 1.31. The company’s 50 day moving average is $25.50 and its two-hundred day moving average is $24.20.

Enovis (NYSE:ENOV – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The business had revenue of $582.78 million during the quarter, compared to analyst estimates of $581.84 million. During the same period in the prior year, the business posted $0.79 earnings per share. The company’s revenue was up 3.2% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, research analysts anticipate that Enovis Corporation will post 3.15 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ENOV shares. Zacks Research raised Enovis from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 29th. BMO Capital Markets set a $27.00 price objective on Enovis in a report on Tuesday. Citigroup reiterated a “market outperform” rating on shares of Enovis in a research report on Wednesday. Canaccord Genuity Group lowered their target price on Enovis from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Monday, August 17th. Finally, Wall Street Zen cut Enovis from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $40.38.

View Our Latest Report on Enovis

Insider Transactions at Enovis

In other Enovis news, insider Oliver Engert acquired 5,140 shares of the stock in a transaction dated Thursday, September 3rd. The shares were acquired at an average cost of $19.46 per share, for a total transaction of $100,024.40. Following the completion of the transaction, the insider directly owned 61,238 shares of the company’s stock, valued at approximately $1,191,691.48. The trade was a 9.16% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Damien Mcdonald bought 13,035 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were acquired at an average cost of $19.15 per share, for a total transaction of $249,620.25. Following the purchase, the chief executive officer directly owned 247,077 shares in the company, valued at $4,731,524.55. This trade represents a 5.57% increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders have acquired 23,833 shares of company stock worth $469,455. Insiders own 2.90% of the company’s stock.

Key Enovis News

Here are the key news stories impacting Enovis this week:

  • Positive Sentiment: CEO Damien McDonald bought 13,035 shares for approximately $249,620, increasing his stake by 5.57%. A substantial open-market purchase by the chief executive may signal confidence that the recent selloff has pushed the stock below its perceived value. SEC filing on CEO purchase
  • Positive Sentiment: Insider Oliver Engert purchased 5,140 shares worth approximately $100,024, raising his ownership by 9.16%. The additional insider buying provides another potential confidence signal for investors. SEC filing on insider purchase
  • Positive Sentiment: Zacks upgraded Enovis to Rank #2, or “Buy,” citing improving earnings prospects. Analysts’ upward earnings revisions and technically oversold conditions also suggest the possibility of a near-term trend reversal. Zacks Buy rating article
  • Positive Sentiment: Canaccord Genuity maintained a Buy rating on ENOV, reinforcing the view that the selloff may have created an attractive entry point. Canaccord Genuity rating article
  • Neutral Sentiment: A Q2 comparison with other specialty medical-device companies provides industry context, but the item does not identify a new material change to Enovis’ outlook. Q2 earnings comparison
  • Negative Sentiment: Wells Fargo lowered its ENOV price target to $33, while Citizens JMP reduced its target to $47. Although both targets remain above the current trading range, the cuts indicate more cautious valuation assumptions and may weigh on sentiment. Wells Fargo price-target article Citizens JMP price-target article

About Enovis

(Free Report)

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.

Featured Stories

Institutional Ownership by Quarter for Enovis (NYSE:ENOV)

Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.